Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
21 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250721376367/en/Lantern-Pharma-Secures-EU-Patent-Allowance-for-LP-284-Bolstering-Global-IP-Position-for-AI-Developed-Cancer-Therapy
15 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250715020079/en/Lantern-Pharma-Unveils-Groundbreaking-AI-Powered-Module-to-Predict-Activity-and-Efficacy-of-Combination-Regimens-in-Clinical-Cancer-Treatment
29 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250529981828/en/Lantern-Pharmas-LP-184-Shows-Promising-In-Vivo-Activity-in-Atypical-Teratoid-Rhabdoid-Tumors-ATRT-at-SNO-Pediatric-Conference-Further-Validating-Rare-Pediatric-Disease-Designation-and-Pathway-to-Clinical-Trials
15 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250515899750/en/Lantern-Pharma-Reports-First-Quarter-2025-Financial-Results-and-Business-Updates
12 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250512968719/en/Lantern-Pharma-Secures-FDA-Clearance-for-Planned-Phase-1b2-Trial-of-LP-184-in-Biomarker-Defined-Treatment-Resistant-NSCLC-Patients-with-High-Unmet-Clinical-Need
08 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250508864284/en/Lantern-Pharma-to-Report-First-Quarter-2025-Operating-Financial-Results-on-May-15th-2025-at-900-a.m.-ET
ABOUT THIS PAGE